Immunomedics Hit With Investor Suit To Halt $21B Gilead Deal
An Immunomedics investor has filed a proposed class action in Delaware federal court seeking to halt the company's $21 billion sale to biopharmaceutical giant Gilead Sciences, saying key information has been...To view the full article, register now.
Already a subscriber? Click here to view full article